Bristol Myers Squibb reported exceptional third-quarter earnings exceeding expectations, driven by Eliquis and growth portfolio drugs. The company raised revenue and earnings guidance for 2024 amidst cost-cutting efforts to enhance key drug brands and R&D programs.